A multicenter prospective cohort study on hepatocarcinogenesis in patients with chronic hepatitis C after sustained virological response to direct acting antivirals

A multicenter prospective cohort study on hepatocarcinogenesis in patients with chronic hepatitis C after sustained virological response to direct acting antivirals - A prospective cohort study on hepatocarcinogenesis in patients with chronic hepatitis C after sustained virological response

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016982

Enrollment

300

Registered

2015-04-01

Start date

2015-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C after sustained virological response

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with chronic hepatitis C or compensated cirrhosis who achieved sustained virological response to either treatments as follows; a) Direct acting antivirals in combination with peginterferon and rivabirin; b) Interferon-free regimen with direct acting antivirals. 2) Patients without history of hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: 1) Patients with Child-Pugh class C. 2) HBsAg-positive patients. 3) Patients who have malignant neoplasm.

Design outcomes

Primary

Measure	Time frame
Disease-free survival	—

Countries

Japan

Contacts

Public ContactYasunori Kawaguchi

Saga-ken Medical Centre Koseikan Hepatobiliary-pancreatology

kawaguy222@gmail.com0952-24-2171

Outcome results